Patents by Inventor William A. Gaarde

William A. Gaarde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120184031
    Abstract: The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.
    Type: Application
    Filed: January 17, 2012
    Publication date: July 19, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Susan M. Freier, Muthiah Manoharan, William A. Gaarde, Richard H. Griffey, Eric E.` Swayze, C. Frank Bennett
  • Patent number: 8076306
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: December 13, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, C. Frank Bennett, William A. Gaarde, Trisha Lockhart, Robert McKay
  • Publication number: 20110213011
    Abstract: Provided are compounds capable of inhibiting SMAD3 and compositions containing same as well as methods using such compounds for treating fibrosis and scarring.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Susan M. Freier, C. Frank Bennett, William A. Gaarde
  • Publication number: 20110172296
    Abstract: Provided are compounds capable of inhibiting expression of TGF-beta 1 and compositions containing same as well as methods using such compounds for treating fibrotic diseases including the reduction of scarring resulting from wound healing.
    Type: Application
    Filed: January 12, 2011
    Publication date: July 14, 2011
    Inventors: C. Frank Bennett, Susan M. Freier, Nicholas M. Dean, J. Gordon Foulkes, William A. Gaarde
  • Patent number: 7507810
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-?, airway hyperresponsiveness, and/or pulmonary inflammation.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: March 24, 2009
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: James G. Karras, Susan Gregory, Susan M. Freier, William A. Gaarde, Mausumee Guha
  • Patent number: 6809193
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: October 26, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Robert McKay, Nicholas M. Dean, Brett P. Monia, Pamela Nero, William A. Gaarde
  • Publication number: 20040192628
    Abstract: Compounds, compositions and methods are provided for inhibiting FAK mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding FAK. Methods of using these antisense compounds for inhibition of FAK expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of FAK are provided.
    Type: Application
    Filed: August 22, 2003
    Publication date: September 30, 2004
    Inventors: Brett P. Monia, William A. Gaarde, Pamela S. Nero
  • Publication number: 20040171566
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Application
    Filed: August 15, 2003
    Publication date: September 2, 2004
    Inventors: Brett P. Monia, William A. Gaarde, Pamela Nero, Robert McKay, Wai Shiu Fred Wong
  • Publication number: 20040033976
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK3. Methods of using these compounds for modulation of MEKK3 expression and for treatment of diseases associated with expression of MEKK3 are provided.
    Type: Application
    Filed: June 13, 2003
    Publication date: February 19, 2004
    Inventors: Donna T. Ward, William A. Gaarde, Brett P. Monia, Jacqueline R. Wyatt
  • Publication number: 20040029823
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
    Type: Application
    Filed: January 15, 2003
    Publication date: February 12, 2004
    Inventors: Robert McKay, Nicholas M. Dean, Brett P. Monia, Pamela S. Nero, William A. Gaarde
  • Publication number: 20030212018
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK2. Methods of using these compounds for modulation of MEKK2 expression and for treatment of diseases associated with expression of MEKK2 are provided.
    Type: Application
    Filed: October 25, 2002
    Publication date: November 13, 2003
    Inventors: Brett P. Monia, William A. Gaarde, Donna T. Ward, Susan M. Freier, Jacqueline Wyatt
  • Publication number: 20030176383
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Application
    Filed: September 9, 2002
    Publication date: September 18, 2003
    Inventors: Brett P. Monia, William A. Gaarde, Pamela Nero, Robert McKay
  • Publication number: 20030004120
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
    Type: Application
    Filed: January 31, 2001
    Publication date: January 2, 2003
    Inventors: Robert McKay, Nicholas M. Dean, Brett P. Monia, Pamela Nero, William A. Gaarde
  • Patent number: 6492171
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TERT. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TERT. Methods of using these compounds for modulation of TERT expression and for treatment of diseases associated with expression of TERT are provided.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: December 10, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Susan M. Freier, Edward Wancewicz
  • Patent number: 6448079
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: September 10, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Pamela Nero, Robert McKay
  • Publication number: 20020045588
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TERT. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TERT. Methods of using these compounds for modulation of TERT expression and for treatment of diseases associated with expression of TERT are provided.
    Type: Application
    Filed: December 7, 2000
    Publication date: April 18, 2002
    Inventors: Brett P. Monia, William A. Gaarde, Susan M. Freier, Edward Wancewicz
  • Patent number: 6331399
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TERT. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TERT. Methods of using these compounds for modulation of TERT expression and for treatment of diseases associated with expression of TERT are provided.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: December 18, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Edward Wancewicz
  • Publication number: 20010034329
    Abstract: Compounds, compositions and methods are provided for inhibiting FAK mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding FAK. Methods of using these antisense compounds for inhibition of FAK expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of FAK are provided.
    Type: Application
    Filed: January 9, 2001
    Publication date: October 25, 2001
    Inventors: Brett P. Monia, William A. Gaarde, Pamela S. Nero
  • Patent number: 6221850
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. The invention is thus directed to compositions for modulating, diagnostic methods for detecting, and therapeutic methods for inhibiting, the hyperproliferation of cells and formation, development and maintenance of tumors.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: April 24, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Nicholas Dean, Brett P. Monia, Pamela Scott Nero, William A. Gaarde
  • Patent number: 6140124
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: October 31, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Pamela S. Nero, Robert McKay